8-K: Karyopharm Therapeutics Q1 2026 Earnings & Clinical Updates

Karyopharm Therapeutics reported Q1 2026 financial results, highlighting $35.1M in total revenue and progress in key clinical trials for selinexor.

Summary

• Karyopharm Therapeutics announced its financial results for the first quarter of 2026, reporting total revenue of $35.1 million, an increase from $30.0 million in Q1 2025.
• U.S. XPOVIO net product revenue reached $29.2 million in Q1 2026, up from $21.1 million in Q1 2025, though demand was impacted by new competitive entrants.
• Enrollment has been completed for the Phase 3 XPORT-EC-042 trial in endometrial cancer, with topline data expected mid-2026.
• Phase 3 SENTRY trial results for myelofibrosis were accepted for presentation at ASCO, showing a statistically significant spleen volume reduction benefit.
• The company reaffirms its full-year 2026 total revenue guidance of $130 million to $150 million, with U.S. XPOVIO net product revenue projected between $115 million and $130 million.
• Operating loss improved by 20% to $26.8 million in Q1 2026 from $33.3 million in Q1 2025.
• Net loss for Q1 2026 was $22.4 million, or $1.02 per basic share, an improvement from a net loss of $23.5 million, or $2.77 per basic share, in Q1 2025.
• Cash, cash equivalents, and restricted cash totaled $91.2 million as of March 31, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing, with key clinical trial milestones achieved and revenue growth, but tempered by competitive pressures and ongoing financial challenges.

Positives

• Total revenue increased to $35.1 million in Q1 2026 from $30.0 million in Q1 2025.
• U.S. XPOVIO net product revenue increased to $29.2 million in Q1 2026 from $21.1 million in Q1 2025.
• Royalty revenue increased to $1.9 million in Q1 2026 from $1.7 million in Q1 2025.
• Enrollment completed for the Phase 3 XPORT-EC-042 trial in endometrial cancer.
• Phase 3 SENTRY trial in myelofibrosis met its first co-primary endpoint for spleen volume reduction.
• A promising overall survival signal was observed in the Phase 3 SENTRY trial.
• Loss from operations decreased by 20% to $26.8 million in Q1 2026.
• Cash position increased to $91.2 million as of March 31, 2026.

Negatives

• Demand for XPOVIO was lower in Q1 2026 compared to Q1 2025 due to new competitive entrants.
• The Phase 3 SENTRY trial did not meet its second co-primary endpoint for mean change in absolute total symptom score.
• Interest expense increased to $12.6 million in Q1 2026 from $11.0 million in Q1 2025 due to higher outstanding debt and interest rates.
• License and other revenue decreased to $5.9 million in Q1 2026 from $9.0 million in Q1 2025.
• Substantial doubt exists regarding Karyopharm's ability to continue as a going concern.
• The company's total liabilities ($397.1 million) significantly exceed its total assets ($131.4 million), resulting in a substantial stockholders deficit ($265.6 million).

Risks

• Competition from new entrants impacting XPOVIO demand.
• Potential for delays in clinical trial data readouts or regulatory submissions.
• The company's ability to continue as a going concern.
• The substantial stockholders deficit and high level of liabilities.
• Uncertainty regarding the adoption of XPOVIO in the commercial marketplace.
• The ability to obtain and maintain regulatory approval for drug candidates.
• Risks associated with clinical trial enrollment and execution.
• Potential for unplanned cash requirements and expenditures.

Future Outlook

Karyopharm reaffirms its full-year 2026 total revenue guidance of $130 million to $150 million, with U.S. XPOVIO net product revenue projected between $115 million and $130 million. R&D and SG&A expenses are expected to be between $230 million and $245 million. The company anticipates its current liquidity will fund operations into late Q3 2026.

Management Comments

• "As we move through 2026, Karyopharm is in a pivotal period with meaningful clinical and regulatory milestones ahead."
• "Through the second and third quarters of 2026, we expect several important developments that have the potential to create significant value for the Company, while improving outcomes for patients."
• "In endometrial cancer, we have completed enrollment in our Phase 3 XPORT-EC-042 trial and remain on track to report topline data in mid-2026."
• "In myelofibrosis, the Phase 3 SENTRY results reinforced the potential of selinexor to meaningfully improve patient outcomes, including a statistically significant SVR35 benefit and a promising overall survival signal."
• "With the endometrial cancer readout ahead and the myelofibrosis regulatory and guideline path coming into focus, we believe these programs could meaningfully expand the impact and long-term opportunity of the selinexor franchise."

Industry Context

StockSavvy.ai notes that Karyopharm Therapeutics is operating in the competitive oncology market, with its lead drug XPOVIO facing new competitors. The company's progress in clinical trials for endometrial cancer and myelofibrosis, if successful, could significantly expand the therapeutic landscape for selinexor.

Comparison to Industry Standards

• The Phase 3 SENTRY trial in myelofibrosis met its primary endpoint of spleen volume reduction (SVR35) at week 24, a key metric for assessing treatment efficacy in this rare blood cancer.
• The company's revenue guidance of $130-$150 million for 2026 positions it within the range of many mid-cap biopharmaceutical companies focused on commercializing oncology drugs.
• The net loss of $22.4 million in Q1 2026, while significant, represents an improvement over the prior year, reflecting efforts towards operational efficiency common in the pharmaceutical development phase.

Stakeholder Impact

• Shareholders: Potential for increased value if clinical trial data is positive and regulatory approvals are obtained, but also risks associated with the company's going concern status and substantial deficit.
• Patients: Continued access to XPOVIO and potential for new treatment options with selinexor in endometrial cancer and myelofibrosis.
• Partners (Menarini, Antengene, etc.): Continued royalty revenue from ex-U.S. sales of selinexor.

Next Steps

• Present Phase 3 SENTRY trial results at ASCO on June 2.
• Engage with the FDA and other global regulatory agencies regarding the SENTRY trial data and sNDA filing plan.
• Announce topline data from the Phase 3 XPORT-EC-042 trial in mid-2026.
• Announce topline data from the 60 mg cohort of the Phase 2 SENTRY-2 trial in the second half of 2026.
• Announce topline data from the Phase 3 XPORT-MM-031 (EMN29) trial in the second half of 2026.
• Continue to fund current operating plans into late in the third quarter of 2026.

Key Dates

Recommendation

The company shows progress in clinical development and revenue growth, but faces significant competition and financial risks, including substantial debt and a going concern warning. A 'hold' recommendation reflects the balance of potential upside from clinical catalysts against these considerable risks.

Keywords

Karyopharm Therapeutics, KPTI, XPOVIO, selinexor, endometrial cancer, myelofibrosis, clinical trials, financial results